A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Ruxolitinib deuterated (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to a Concert Pharmaceuticals media release, the company expects to complete the trial in the second half of 2018.
    • 17 Jul 2017 Number of arms has changed from 5 to 3,hence number of patients has also changed from100 to 90.
    • 11 Jul 2017 Planned number of patients changed from 100 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top